{"product_id":"300147sz-ansoff-matrix","title":"Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): Ansoff Matrix","description":"\u003cp\u003eIn the ever-evolving landscape of the pharmaceutical industry, growth often hinges on strategic decision-making. The Ansoff Matrix offers a robust framework, guiding companies like Xiangxue Pharmaceutical Co., Ltd. in navigating opportunities for expansion. From market penetration to diversification, each strategy presents unique pathways for enhancing market presence and innovating product offerings. Dive into the insights below to explore how this analytical tool can empower business leaders and entrepreneurs to drive sustainable growth.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eXiangxue Pharmaceutical Co.,Ltd. - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\n\u003ch3\u003eIncrease market share by enhancing marketing efforts and promotional activities for existing products.\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical has experienced significant growth, with revenue reaching approximately \u003cstrong\u003eRMB 2.43 billion\u003c\/strong\u003e in 2022, reflecting a \u003cstrong\u003e8.35%\u003c\/strong\u003e year-over-year increase. The company has implemented a robust marketing strategy focusing on digital platforms and traditional methods, increasing its advertising spending by \u003cstrong\u003e15%\u003c\/strong\u003e in 2023. Their flagship products, including the anti-tumor drug BBI-4000, have gained a competitive edge due to targeted marketing campaigns.\u003c\/p\u003e\n\n\u003ch3\u003eStrengthen customer loyalty programs to reduce churn and increase repeat purchases.\u003c\/h3\u003e\n\u003cp\u003eThe introduction of a loyalty program in early 2023 has shown promise, with the company's customer retention rate improving to \u003cstrong\u003e85%\u003c\/strong\u003e. This initiative has resulted in an increase of repeat purchases by approximately \u003cstrong\u003e20%\u003c\/strong\u003e among active members. Xiangxue's loyalty program includes discounts and special offers for returning customers, which have been well-received in their key markets.\u003c\/p\u003e\n\n\u003ch3\u003eFocus on competitive pricing strategies to attract price-sensitive customers.\u003c\/h3\u003e\n\u003cp\u003eXiangxue has adopted competitive pricing strategies, reducing the prices of select generic medications by up to \u003cstrong\u003e10%\u003c\/strong\u003e to gain market traction. This pricing adjustment has led to a \u003cstrong\u003e12%\u003c\/strong\u003e increase in sales volume for its generics line in the first half of 2023. The company’s analysis indicated a market opportunity with price-sensitive consumers, especially in tier-two and tier-three cities in China.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance distribution efficiency to ensure product availability in key locations.\u003c\/h3\u003e\n\u003cp\u003eIn 2023, Xiangxue Pharmaceutical invested \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e to enhance its distribution network, resulting in an improved distribution efficiency rate of \u003cstrong\u003e92%\u003c\/strong\u003e. The establishment of additional regional warehouses has decreased product delivery times to pharmacies and hospitals by approximately \u003cstrong\u003e25%\u003c\/strong\u003e, ensuring higher product availability and customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eOptimize supply chain processes to reduce costs and improve product delivery times.\u003c\/h3\u003e\n\u003cp\u003eThe recent optimization of Xiangxue’s supply chain has led to reductions in operational costs by \u003cstrong\u003e5%\u003c\/strong\u003e. By implementing advanced data analytics in inventory management, the company has streamlined its supply chain processes, which has improved product delivery times by an average of \u003cstrong\u003e30%\u003c\/strong\u003e. This efficiency gain positively impacts their profitability margin, which now stands at \u003cstrong\u003e18%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eRevenue (RMB billion)\u003c\/th\u003e\n        \u003cth\u003eMarketing Spend Increase (%)\u003c\/th\u003e\n        \u003cth\u003eCustomer Retention Rate (%)\u003c\/th\u003e\n        \u003cth\u003eSales Volume Increase for Generics (%)\u003c\/th\u003e\n        \u003cth\u003eDistribution Efficiency Rate (%)\u003c\/th\u003e\n        \u003cth\u003eOperational Cost Reduction (%)\u003c\/th\u003e\n        \u003cth\u003eProfit Margin (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e2.24\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n        \u003ctd\u003e80\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n        \u003ctd\u003e88\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n        \u003ctd\u003e16\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e2.43\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003e83\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n        \u003ctd\u003e90\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n        \u003ctd\u003e17\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003e2.64 (Projected)\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003e85\u003c\/td\u003e\n        \u003ctd\u003e12\u003c\/td\u003e\n        \u003ctd\u003e92\u003c\/td\u003e\n        \u003ctd\u003e5\u003c\/td\u003e\n        \u003ctd\u003e18\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eXiangxue Pharmaceutical Co.,Ltd. - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\n\u003ch3\u003eExplore new geographic regions, both domestically and internationally, to expand market reach.\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical has made significant strides in expanding its geographic presence. In 2022, the company reported a revenue increase of \u003cstrong\u003e21.4%\u003c\/strong\u003e, primarily attributed to its expansion efforts in Southeast Asia and Africa. The company aims to penetrate markets like Thailand, Malaysia, and Nigeria, which collectively represent a pharmaceutical market valued at approximately \u003cstrong\u003e$20 billion\u003c\/strong\u003e in 2023.\u003c\/p\u003e\n\n\u003ch3\u003eTarget new customer segments or demographics that have not yet been fully tapped.\u003c\/h3\u003e\n\u003cp\u003eThe company is actively targeting the aging population in China, projected to reach \u003cstrong\u003e487 million\u003c\/strong\u003e by 2050. Xiangxue has developed tailored products that cater to geriatric health needs, resulting in an increase in demand for its healthcare offerings. In its latest earnings report for Q2 2023, sales from products aimed at elder care grew by \u003cstrong\u003e34%\u003c\/strong\u003e compared to the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eAdjust marketing strategies to appeal to regional preferences and cultural nuances.\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical has adapted its marketing strategies based on regional preferences. In 2023, they launched a marketing campaign in southern China focusing on traditional medicine integrations, which saw a \u003cstrong\u003e15%\u003c\/strong\u003e increase in sales in that region. The campaign included localized advertisements on social media platforms, leading to a customer engagement rate increase of \u003cstrong\u003e40%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eEstablish partnerships with local distributors or retailers to facilitate market entry.\u003c\/h3\u003e\n\u003cp\u003eIn 2022, Xiangxue Pharmaceutical partnered with over \u003cstrong\u003e50 local distributors\u003c\/strong\u003e across various countries to enhance its distribution network. This strategy has allowed the company to achieve a distribution footprint covering more than \u003cstrong\u003e60%\u003c\/strong\u003e of retail pharmacies in those markets. The partnerships have resulted in a \u003cstrong\u003e30%\u003c\/strong\u003e increase in market penetration in new regions.\u003c\/p\u003e\n\n\u003ch3\u003eUtilize digital marketing to reach new markets with lower entry costs.\u003c\/h3\u003e\n\u003cp\u003eDigital marketing has become a cornerstone of Xiangxue's market development strategy. The company allocated \u003cstrong\u003e$5 million\u003c\/strong\u003e to its digital campaigns in 2023, focusing on online health platforms and e-commerce channels. This investment has yielded a \u003cstrong\u003e25%\u003c\/strong\u003e increase in online sales, predominantly from younger demographics, which have shown a growing preference for digital purchasing options.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging Population Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e487 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2050 Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Growth in Elder Care Products\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Increase from Localized Campaign\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEngagement Rate Increase from Campaign\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal Distributors\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution Coverage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Penetration Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Marketing Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Sales Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eXiangxue Pharmaceutical Co.,Ltd. - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003ch3\u003eInvest in research and development to innovate and improve existing pharmaceutical products.\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical Co., Ltd. allocated approximately \u003cstrong\u003e8% of its total revenue\u003c\/strong\u003e to research and development in recent years. For the fiscal year 2022, the company's revenue was reported at approximately \u003cstrong\u003eCNY 4 billion\u003c\/strong\u003e, resulting in an R\u0026amp;D investment of around \u003cstrong\u003eCNY 320 million\u003c\/strong\u003e. This investment focuses on enhancing therapeutic efficacy and safety profiles of existing products.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop new products that cater to emerging health needs and consumer preferences.\u003c\/h3\u003e\n\u003cp\u003eIn 2023, Xiangxue launched \u003cstrong\u003e15 new products\u003c\/strong\u003e, including several targeted at chronic diseases prevalent in an aging population. The company's focus on traditional Chinese medicine combined with modern pharmaceutical techniques has resulted in a projected market share increase of \u003cstrong\u003e3%\u003c\/strong\u003e within the expanding herbal supplement market, valued at approximately \u003cstrong\u003eCNY 80 billion\u003c\/strong\u003e in 2022.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborate with healthcare professionals to create products that address specific medical challenges.\u003c\/h3\u003e\n\u003cp\u003eXiangxue partnered with over \u003cstrong\u003e20 hospitals and research institutions\u003c\/strong\u003e in 2023 to co-develop compounds targeting autoimmune diseases. This collaborative effort has led to the successful advancement of \u003cstrong\u003efive new drug candidates\u003c\/strong\u003e currently in clinical trials. The potential market for these drugs is estimated to exceed \u003cstrong\u003eCNY 5 billion\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance product features and formulations to maintain competitive advantage.\u003c\/h3\u003e\n\u003cp\u003eThe company has improved its flagship product formulations, resulting in a \u003cstrong\u003e15% increase\u003c\/strong\u003e in overall effectiveness as per clinical studies completed in 2022. Additionally, enhancements in the delivery mechanism of its products have led to a \u003cstrong\u003e25% reduction\u003c\/strong\u003e in side effects reported by users. These improvements are expected to lead to a \u003cstrong\u003e10% increase\u003c\/strong\u003e in sales for the following year.\u003c\/p\u003e\n\n\u003ch3\u003eImplement customer feedback mechanisms to guide product improvement initiatives.\u003c\/h3\u003e\n\u003cp\u003eXiangxue has developed an online feedback portal that has received over \u003cstrong\u003e10,000 responses\u003c\/strong\u003e since its launch in 2023. This initiative has guided enhancements in at least \u003cstrong\u003e3 product lines\u003c\/strong\u003e, modifying formulations according to patient feedback, with a resultant \u003cstrong\u003e5% increase\u003c\/strong\u003e in customer satisfaction ratings based on a follow-up survey.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eRevenue (CNY)\u003c\/th\u003e\n    \u003cth\u003eR\u0026amp;D Investment (CNY)\u003c\/th\u003e\n    \u003cth\u003eNew Products Launched\u003c\/th\u003e\n    \u003cth\u003eMarket Share Increase (%)\u003c\/th\u003e\n    \u003cth\u003eClinical Trials Progress\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e3.5 billion\u003c\/td\u003e\n    \u003ctd\u003e280 million\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n    \u003ctd\u003e2\u003c\/td\u003e\n    \u003ctd\u003e4 drug candidates\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e4 billion\u003c\/td\u003e\n    \u003ctd\u003e320 million\u003c\/td\u003e\n    \u003ctd\u003e15\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n    \u003ctd\u003e5 drug candidates\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2023\u003c\/td\u003e\n    \u003ctd\u003e4.5 billion (projected)\u003c\/td\u003e\n    \u003ctd\u003e360 million (projected)\u003c\/td\u003e\n    \u003ctd\u003e20 (projected)\u003c\/td\u003e\n    \u003ctd\u003e4 (projected)\u003c\/td\u003e\n    \u003ctd\u003e6 drug candidates\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eXiangxue Pharmaceutical Co.,Ltd. - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\n\u003ch3\u003eEnter new industries or sectors that complement the current pharmaceutical offerings\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical has been actively seeking to enter new sectors that provide synergy with its pharmaceutical operations. In 2022, the company generated revenue of approximately \u003cstrong\u003eRMB 3.20 billion\u003c\/strong\u003e, with plans to diversify into related fields such as healthcare services and medical devices. By 2023, the company aimed to allocate \u003cstrong\u003e15%\u003c\/strong\u003e of its R\u0026amp;D budget towards these new sectors.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop wellness or health-related products beyond traditional pharmaceuticals\u003c\/h3\u003e\n\u003cp\u003eThe company has expanded its product line to include nutraceuticals and wellness products. For instance, its health supplement line, launched in 2022, brought in \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e in revenue within the first year. Xiangxue Pharmaceutical reported that the global wellness market is projected to grow to \u003cstrong\u003e$4.2 trillion\u003c\/strong\u003e by 2024, offering substantial growth opportunities.\u003c\/p\u003e\n\n\u003ch3\u003eExplore opportunities in biotechnology or personalized medicine for future growth\u003c\/h3\u003e\n\u003cp\u003eXiangxue Pharmaceutical has invested heavily in biotechnology. The company has earmarked over \u003cstrong\u003eRMB 1 billion\u003c\/strong\u003e for its biotech division within a five-year plan. Furthermore, personalized medicine is a focus area, with the global personalized medicine market expected to reach \u003cstrong\u003e$2.45 trillion\u003c\/strong\u003e by 2026. In 2022, the company's revenue from biotech products alone accounted for \u003cstrong\u003e20%\u003c\/strong\u003e of total pharmaceutical sales.\u003c\/p\u003e\n\n\u003ch3\u003eAcquire or establish joint ventures with companies in different but related markets\u003c\/h3\u003e\n\u003cp\u003eTo accelerate its diversification strategy, Xiangxue Pharmaceutical entered a joint venture with a leading biotechnology firm, with the agreement finalized in mid-2023. The initial investment for this venture amounts to \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e. This partnership aims to develop advanced therapies and leverage complementary technologies, anticipating a boost in revenues of around \u003cstrong\u003e30%\u003c\/strong\u003e over the next three years.\u003c\/p\u003e\n\n\u003ch3\u003eSpread business risks by investing in diverse product lines and markets\u003c\/h3\u003e\n\u003cp\u003eDiversification serves as a risk mitigation strategy. As of 2023, Xiangxue Pharmaceutical's product portfolio spans over \u003cstrong\u003e200\u003c\/strong\u003e different pharmaceutical and health-related products, distributed across various therapeutic areas. Furthermore, the company has expanded its market reach to over \u003cstrong\u003e30 countries\u003c\/strong\u003e, thereby reducing reliance on domestic sales, which constituted only \u003cstrong\u003e60%\u003c\/strong\u003e of total revenues as of the latest fiscal year. The management aims to increase international sales contribution to \u003cstrong\u003e40%\u003c\/strong\u003e by 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eRevenue (RMB)\u003c\/th\u003e\n        \u003cth\u003eHealth Products Revenue (RMB)\u003c\/th\u003e\n        \u003cth\u003eBiotech R\u0026amp;D Investment (RMB)\u003c\/th\u003e\n        \u003cth\u003eGlobal Wellness Market Growth\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.00 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.9%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.20 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e4.1%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023 (Projected)\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e3.70 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e900 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e4.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003cp\u003eUnderstanding the Ansoff Matrix provides Xiangxue Pharmaceutical Co., Ltd. with a strategic framework to navigate their growth through market penetration, development, product innovation, and diversification. By leveraging these approaches, decision-makers can effectively evaluate and seize opportunities, ensuring the company not only thrives in the competitive pharmaceutical landscape but also adapts to changing consumer demands and market dynamics.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45675513381013,"sku":"300147sz-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/300147sz-ansoff-matrix.png?v=1739124053","url":"https:\/\/dcf-model.com\/es\/products\/300147sz-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}